Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SRI Speeds Development of Genome-Scale Models of Metabolic Networks

Published: Wednesday, January 25, 2012
Last Updated: Wednesday, January 25, 2012
Bookmark and Share
The new MetaFlux functionality can be used to design drugs against disease-causing bacteria and metabolically engineer bacteria to make chemicals and fuels.

MetaFlux is a new software tool to substantially decrease the time required for researchers to construct genome-scale models of metabolic networks.

Metabolic networks are the complete set of metabolic and physical processes that determine the physiological and biochemical properties of a cell. Genome-scale models are used to predict cell growth rate, combinations of chemicals that can support cell growth, and which genes will cause cell death if they are inactivated.

It may also yield insights about growth of bacteria that cannot currently be grown in a laboratory.
MetaFlux software couples flux balance analysis (FBA), a mathematical method to analyze metabolism, with pathway databases that contain information about the network of interactions between proteins and small molecules that forms the biochemical factory of a cell.

"Genome-scale models are very time consuming to construct, because they require an exact description of the hundreds of biochemical reactions within a cell—and a single missing reaction can render a model nonfunctional," said Peter D. Karp, Ph.D., director, Bioinformatics Research Group, SRI International. "Our goals were to speed up the development of these models and allow a wider community of scientists to build them. SRI's Bioinformatics Research group has already developed two different FBA models using MetaFlux, each within one month of effort."

Based on mixed integer linear programming, MetaFlux uses a multiple gap-filling method to accelerate the development of FBA models. This method generates the models directly from pathway/genome databases, which can be constructed, queried, and visualized using SRI's Pathway Tools software. MetaFlux can also suggest additional reactions, nutrients, and secreted metabolites to complete a model.

During model development, MetaFlux will identify the subset of biomass metabolites (end products of biosynthesis) that cannot currently be produced. The software also paints reaction flux rates onto an automatically generated organism-specific metabolic map diagram, much like an online road map shows traffic flow rates.

MetaFlux is part of Pathway Tools, available freely to academic users and for a fee to commercial users. An article describing MetaFlux is in the online edition of the journal Bioinformatics at http://oxford.ly/metaflux, and will appear in the journal's 3rd issue of 2012, which publishes in early February.

The project described was supported by award number R01GM080746 from the National Institute of General Medical Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SRI Awarded NIAID Contract to Study New HIV and AIDS Therapies
The $49M, seven-year contract with the National Institute of Allergy and Infectious Diseases will see SRI conduct preclinical development of potential therapies for HIV infection and AIDS.
Friday, August 01, 2014
SRI Establishes Metabolite Standards Synthesis Center for NHLBI
Company receives $4.5 million contract from the NHLBI to establish a Metabolite Standards Synthesis Center to prepare molecules for researchers to use in the field of metabolomics.
Tuesday, January 07, 2014
DOE Funds SRI to Enhance Bioinformatics Tools for Renewable Energy Research
Department of Energy-funded project will develop enhanced tools to accelerate bioenergy research.
Sunday, January 30, 2011
Scientific News
Head Injury Patients have Protein Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
Exposure to Air Pollution 30 Years Ago Associated with Increased Risk of Death
Exposure to air pollution more than 30 years ago may still affect an individual's mortality risk today, according to new research from Imperial College London.
More Then 1 in 20 U.S. Children have Dizziness and Balance Problems
Researchers at NIH have found that girls have a higher prevalence of dizziness and balance problems compared to boys, 5.7 percent and 5.0 percent.
Biosensors on Demand
New strategy results in custom "designer proteins" for sensing a variety of molecules.
Low-Cost, Portable NQR Spectroscopy
A researcher at Case Western Reserve University is developing a low-cost, portable prototype designed to detect tainted medicines and food supplements that otherwise can make their way to consumers. The technology can authenticate good medicines and supplements.
Structure of Brain Plaques in Huntington's
Researchers at the University of Pittsburgh School of Medicine have shown that the core of the protein clumps found in the brains of people with Huntington's disease have a distinctive structure, a finding that could shed light on the molecular mechanisms underlying the neurodegenerative disorder.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Visualizing a Cancer Drug Target at Atomic Resolution
Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!